Azacitidine in fludarabine-refractory chronic lymphocytic Leukemia: A phase II study

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 3, 2013, Pages 292-295

  Malik, Asifa ^a   Shoukier, Mahran ^a   Garcia Manero, Guillermo ^a   Wierda, William ^a   Cortes, Jorge ^a   Bickel, Susan ^a   Keating, Michael J ^a   Estrov, Zeev ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Azacitidine; Chronic lymphocytic leukemia; DNA methylation

Indexed keywords

ALANINE AMINOTRANSFERASE; AZACITIDINE; BILIRUBIN; CREATININE; FLUDARABINE; HEMOGLOBIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CHROMOSOME 11Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DIPLOIDY; DRUG DOSE REDUCTION; EXERCISE TEST; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEPATOSPLENOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KARYOTYPE; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIVER FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RASH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSFUSION; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84877766150     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.11.009     Document Type: Article

References (13)

1. S.A. Parikh, M.J. Keating, S. O'Brien Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia Blood 118 2011 2062 2068
2. M. Hallek, K. Fischer, G. Fingerle-Rowson Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
3. T. Elter, L. Gercheva-Kyuchukova, H. Pylylpenko Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial Lancet Oncol 12 2011 1204 1213
4. X.C. Badoux, M.J. Keating, X. Wang Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia Blood 118 2011 2085 2093
5. W.G. Wierda, S. Padmanabhan, G.W. Chan Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study Blood 118 2011 5126 5129
6. M. Corcoran, A. Parker, J. Orchard ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia Haematologica 90 2005 1078 1088 (Pubitemid 41323507)
7. A. Raval, S.M. Tanner, J.C. Byrd Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia Cell 129 2007 879 890 (Pubitemid 46813150)
8. W.G. Tong, W.G. Wierda, E. Lin Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact Epigenetics 5 2010 499 508
9. R.M. Lyons, T.M. Cosgriff, S.S. Modi Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes J Clin Oncol 27 2009 1850 1856
10. G. Garcia-Manero, S.D. Gore, C. Cogle Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia J Clin Oncol 29 2011 2521 2527
11. J. Aimiuwu, H. Wang, P. Chen RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia Blood 119 2012 5229 5238
12. F. Braiteh, A.O. Soriano, G. Garcia-Manero Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers Clin Cancer Res 14 2008 6296 6301
13. K.A. Blum, Z. Liu, D.M. Lucas Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation Br J Haematol 150 2010 189 195